Human IgG1 monoclonal antibody against alpha-synuclein ( DrugBank: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
17 | 多系統萎縮症 | 1 |
17. 多系統萎縮症
臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2022-000336-28-DE (EUCTR) | 12/12/2022 | 28/07/2022 | A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy | A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy | Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: TAK-341 Product Code: TAK-341 INN or Proposed INN: Not assigned Other descriptive name: Human IgG1 monoclonal antibody against alpha-synuclein | Takeda Development Center Americas, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 138 | Phase 2 | United Kingdom;Italy;Japan;Denmark;Austria;Germany;Portugal;France;United States;Spain |